Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer

被引：71
作者：
Oliveira, Kelly C. S. [1 ]
Ramos, Iago Barroso [2 ]
Silva, Jessica M. C. [1 ]
Barra, Williams Fernandes [1 ]
Riggins, Gregory J. [3 ]
Palande, Vikrant [4 ]
Pinho, Catarina Torres [1 ]
Frenkel-Morgenstern, Milana [4 ]
Santos, Sidney E. B. [1 ]
Assumpcao, Paulo P. [1 ]
Burbano, Rommel R. [5 ]
Calcagno, Danielle Queiroz [1 ]
机构：
[1] Univ Fed Para, Nucleo Pesquisas Oncol, Belem, Para, Brazil
[2] Univ Fed Para, Programa Residencia Multiprofiss Saude, Hosp Univ Joao Barros Barreto, Belem, Para, Brazil
[3] Johns Hopkins Med, Brain Canc Biol & Therapy Res Lab, Baltimore, MD USA
[4] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel
[5] Hosp Ophir Loyola, Lab Biol Mol, Belem, Para, Brazil
来源：
MOLECULAR CANCER RESEARCH | 2020年 / 18卷 / 04期
关键词：
CELL-FREE DNA; ACQUIRED-RESISTANCE; TREATMENT RESPONSE; SYSTEMIC THERAPY; LIQUID BIOPSIES; ESR1; MUTATIONS; PLASMA DNA; GENE; IDENTIFICATION; IMMUNOTHERAPY;
D O I：
10.1158/1541-7786.MCR-19-0768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non-small cell lung cancer.
引用
收藏
页码：517 / 528
页数：12
相关论文
共 92 条
  • [71] Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
    Thierry, A. R.
    El Messaoudi, S.
    Mollevi, C.
    Raoul, J. L.
    Guimbaud, R.
    Pezet, D.
    Artru, P.
    Assenat, E.
    Borg, C.
    Mathonnet, M.
    De La Fouchardiere, C.
    Bouche, O.
    Gavoille, C.
    Fiess, C.
    Auzemery, B.
    Meddeb, R.
    Lopez-Crapez, E.
    Sanchez, C.
    Pastor, B.
    Ychou, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (09) : 2149 - 2159
  • [72] Origins, structures, and functions of circulating DNA in oncology
    Thierry, A. R.
    El Messaoudi, S.
    Gahan, P. B.
    Anker, P.
    Stroun, M.
    [J]. CANCER AND METASTASIS REVIEWS, 2016, 35 (03) : 347 - 376
  • [73] Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
    Thierry, Alain R.
    Mouliere, Florent
    El Messaoudi, Safia
    Mollevi, Caroline
    Lopez-Crapez, Evelyne
    Rolet, Fanny
    Gillet, Brigitte
    Gongora, Celine
    Dechelotte, Pierre
    Robert, Bruno
    Del Rio, Maguy
    Lamy, Pierre-Jean
    Bibeau, Frederic
    Nouaille, Michelle
    Loriot, Virginie
    Jarrousse, Anne-Sophie
    Molina, Franck
    Mathonnet, Muriel
    Pezet, Denis
    Ychou, Marc
    [J]. NATURE MEDICINE, 2014, 20 (04) : 430 - +
  • [74] ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
    Toy, Weiyi
    Shen, Yang
    Won, Helen
    Green, Bradley
    Sakr, Rita A.
    Will, Marie
    Li, Zhiqiang
    Gala, Kinisha
    Fanning, Sean
    King, Tari A.
    Hudis, Clifford
    Chen, David
    Taran, Tetiana
    Hortobagyi, Gabriel
    Greene, Geoffrey
    Berger, Michael
    Baselga, Jose
    Chandarlapaty, Sarat
    [J]. NATURE GENETICS, 2013, 45 (12) : 1439 - U189
  • [75] Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
    Uchibori, Ken
    Inase, Naohiko
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 915 - 925
  • [76] Uchoa Guimaraes Camila Tavares, 2018, Oncotarget, V9, P15144, DOI 10.18632/oncotarget.24540
  • [77] POINT MUTATIONS OF THE N-RAS GENE IN THE BLOOD-PLASMA DNA OF PATIENTS WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOGENOUS LEUKEMIA
    VASIOUKHIN, V
    ANKER, P
    MAURICE, P
    LYAUTEY, J
    LEDERREY, C
    STROUN, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (04) : 774 - 779
  • [78] Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
    Vidal, J.
    Muinelo, L.
    Dalmases, A.
    Jones, F.
    Edelstein, D.
    Iglesias, M.
    Orrillo, M.
    Abalo, A.
    Rodriguez, C.
    Brozos, E.
    Vidal, Y.
    Candamio, S.
    Vazquez, F.
    Ruiz, J.
    Guix, M.
    Visa, L.
    Sikri, V.
    Albanell, J.
    Bellosillo, B.
    Lopez, R.
    Montagut, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1325 - 1332
  • [79] Liquid biopsies come of age: towards implementation of circulating tumour DNA
    Wan, Jonathan C. M.
    Massie, Charles
    Garcia-Corbacho, Javier
    Mouliere, Florent
    Brenton, James D.
    Caldas, Carlos
    Pacey, Simon
    Baird, Richard
    Rosenfeld, Nitzan
    [J]. NATURE REVIEWS CANCER, 2017, 17 (04) : 223 - 238
  • [80] Wang Victoria, 2017, J Thorac Oncol, V12, pe19, DOI 10.1016/j.jtho.2016.11.2217
12345678910